Fresenius SE & Co. KGaA (FSNUF)
| Previous Close | 32.00 |
| Open | 32.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 32.00 - 32.00 |
| 52 Week Range | 19.50 - 32.43 |
| Volume | |
| Avg. Volume | 243 |
| Market Cap | 18.628B |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | 16.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.99 (3.11%) |
| Ex-Dividend Date | May 18, 2023 |
| 1y Target Est | N/A |
- Zacks
Is Fresenius SE & Co. (FSNUY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Simply Wall St.
Fresenius SE & Co. KGaA (ETR:FRE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Most readers would already be aware that Fresenius SE KGaA's (ETR:FRE) stock increased significantly by 20% over the...
- Reuters
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price. Fresenius joins drugmakers Boehringer Ingelheim, Sandoz and Organon, which launched Humira biosimilars, or copies of biologic drugs, this week. Industry experts have said that most new biosimilars are expected to debut with marginal discounts to Humira's monthly price of $6,922.
